Serum discrimination of early-stage lung cancer patients using electrospray-ionization mass spectrometry

Hocker, James R.; Peyton, Marvin D.; Lerner, Megan R.; Mitchell, Stephanie L.; Lightfoot, Stan; Lander, Theresa J.; Bates-Albers, Leah; Vu, Nicole; Hanas, Rushie J.; Kupiec, Thomas C.; Brackett, Daniel J.; Hanas, Jay S.

doi:10.1016/j.lungcan.2011.03.014

Cited by 23 publications

(20 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of significant, distinct mass peaks used here to discriminate (from controls) stage I/II, stage III/IV, stage I, or stage III sera samples are approximately 160, 148, 160, and 149 respectively, out of a range of 1,650 possible m/z-peak values; the LOOCV analysis produces variable significant peak numbers for testing each "left out" sera sample. These relatively large numbers of discriminatory peaks may be necessary for discerning relatively small physiological changes associated with disease states and their progression in line with previous studies (19,29).…”

Section: Discussionsupporting

confidence: 74%

Serum Profiling to Distinguish Early- and Late-Stage Ovarian Cancer Patients from Disease-Free Individuals

Hocker

Bishop

Lightfoot

et al. 2012

Cancer Investigation

Self Cite

View full text Add to dashboard Cite

Sera mass spectrometry (MS) peak differences were analyzed from 35 ovarian cancer patients and 16 disease-free individuals. "Leave one out" cross validation was used to assign "% cancer peaks" in control and ovarian cancer sera samples. Sera MS discriminated stage I/II and stage III/V ovarian cancer patients versus controls with ROC curve area values of 0.82 and 0.92. Test sensitivities for ovarian cancer stage I/II and III/V were 80% and 93% respectively. These results indicate that MS is useful for distinguishing sera from early-stage ovarian cancer patients, and has potential as a test for early detection of this disease.

show abstract

Section: Discussionsupporting

confidence: 74%

Serum Profiling to Distinguish Early- and Late-Stage Ovarian Cancer Patients from Disease-Free Individuals

Hocker

Bishop

Lightfoot

et al. 2012

Cancer Investigation

Self Cite

View full text Add to dashboard Cite

show abstract

“…The study presented here examines the usefulness of deciphering biomolecule patterns in sera from NSCLC adenocarcinoma and squamous cell carcinoma patients using electrospray ionization (ESI) MS. This technology was used for the first time to distinguish the sera molecular patterns of pancreatic cancer patients from controls (10), and more recently for early detection of pancreatic cancer (19). The present study demonstrates potential for distinguishing sera from early-stage NSCLC adenocarcinoma versus squamous cell carcinoma patients as well as from control individuals using this ESI-MS technology.…”

Section: Introductionmentioning

confidence: 72%

“…(11,15,18). The ESI-MS approach used here and previously (10,16,19) has potential advantages over SELDI/MALDI-MS, including allliquid handling, less sample manipulation/grid washings, no chemical additives, and no involvement of random crystallization processes. A potential problem with performing such blood tests from studies that generate large amounts of data, like cDNA arrays and MS, is the phenomenon of "over-fitting. "…”

Section: Identification Of Esi-ms Peak Differences and "Leave One Outmentioning

confidence: 97%

“…Standard quantitative and statistical approaches are proving better for analysis of this data than novel algorithms (11,15). Profiling of sera and other biological fluids is used to catalog disease states and identify biomarker patterns in different cancers, including pancreatic, breast, and lung cancer (10,(16)(17)(18)(19). The study presented here examines the usefulness of deciphering biomolecule patterns in sera from NSCLC adenocarcinoma and squamous cell carcinoma patients using electrospray ionization (ESI) MS.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Distinguishing Non-Small Cell Lung Adenocarcinoma Patients from Squamous Cell Carcinoma Patients and Control Individuals Using Serum Profiling

Hocker¹,

Peyton²,

Lerner³

et al. 2012

Cancer Investigation

Self Cite

View full text Add to dashboard Cite

Goals of this study were to analyze the ability of mass spectrometry serum profiling to distinguish non-small cell lung adenocarcinoma from squamous cell carcinoma patients and healthy controls. Sera were obtained from 19 adenocarcinoma patients, 24 squamous cell carcinoma patients, and 21 controls. Identifications of significant mass-to-charge ratio (m/z) peak differences between these groups were performed using t-tests. A "leave one out" cross-validation procedure yielded discriminatory lung adenocarcinoma versus squamous cell carcinoma p and ROC curve values of <.0001 and 0.92, respectively. Test sensitivity and specificity were 84% and 79%, respectively. This approach could aid in lung cancer diagnosis and sub-typing.

show abstract

“…Previously, we utilized electrospray ionization mass spectrometry (ESI-MS) peaks to distinguish sera from early-stage ovarian, lung, and pancreatic cancer patients from healthy disease-free individuals [15–17,24–26]. In the present study, electrospray serum mass profiling is used to distinguish early-stage PDAC patients (stages I, IIA, IIB) from healthy individuals and from patients with chronic pancreatitis.…”

Section: Introductionmentioning

confidence: 99%

Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling

Hocker

Postier

et al. 2015

Cancer Letters

Self Cite

View full text Add to dashboard Cite

Blood tests are needed to aid in the early detection of pancreatic ductal adenocarcinoma (PDAC), and monitoring pancreatitis development into malignancy especially in high risk patients. This study exhibits efforts and progress toward developing such blood tests, using electrospray-mass spectrometry (MS) serum profiling to distinguish patients with early-stage PDAC or pancreatitis from each other and from controls. Identification of significant serum mass peak differences between these individuals was performed using t tests and “leave one out” cross validation. Serum mass peak distributions of control individuals were distinguished from those of patients with chronic pancreatitis or early-stage PDAC with P values <10−15, and patients with chronic pancreatitis were distinguished from those of patients with early-stage PDAC with a P value <10−12. Sera from 12 out of 12 patients with PDAC stages I, IIA and IIB were blindly validated from controls. Tandem MS/MS identified a cancer phenotype with elements of PDAC involved in early-stage PDAC/control discrimination. These studies indicate electrospray-MS mass profiling can detect serum changes in patients with pancreatitis or early-stage pancreatic cancer. Such technology has the potential to aid in early detection of pancreatic cancer, biomarker development, and in monitoring development of pancreatitis into PDAC.

show abstract

Serum discrimination of early-stage lung cancer patients using electrospray-ionization mass spectrometry

Cited by 23 publications

References 22 publications

Serum Profiling to Distinguish Early- and Late-Stage Ovarian Cancer Patients from Disease-Free Individuals

Serum Profiling to Distinguish Early- and Late-Stage Ovarian Cancer Patients from Disease-Free Individuals

Distinguishing Non-Small Cell Lung Adenocarcinoma Patients from Squamous Cell Carcinoma Patients and Control Individuals Using Serum Profiling

Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling

Contact Info

Product

Resources

About